StockData
Mereo BioPharma Group plc logo

Mereo BioPharma Group plc (MREO) stock

MREONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 1/30
$0.27−0.03 (-10.00%)

Close on Nov 17, 2026Market cap $43.84MP/E –Yield –

Mereo BioPharma Group plc reported revenue of $500.00K for fiscal 2025. Free cash flow was -$22.09M. At the latest close the market valued the company at $43.84M.

Revenue
$500.00K
FY2025
Operating income
-$30.40M
TTM Q3 2026
Free cash flow
-$22.09M
TTM Q3 2026
EPS, diluted
-$0.04
TTM Q3 2026

Key statistics

Valuation at the latest close; fundamentals over fiscal 2025, balances at Sep 30, 2026

Valuation

Market cap
$43.84M
P/E ratio
–
Price to sales
–
Price to book
1.85
Dividend yield
–
Free cash flow yield
-50.39%

Fundamentals

Revenue
$500.00K
Net income
-$26.94M
EPS, diluted
-$0.04
Free cash flow
-$22.09M
Book value per share
$0.03
Diluted shares
805M

Trading

Next earnings
Mar 18, 2027 (estimated, before the open)
Previous close
$0.30
Open
$0.30
Day's range
$0.27 – $0.30
Volume
1,038,163
Average volume (20 days)
683,750
52-week range
$0.20 – $2.37
RSI (14 days)
39.5
Volatility (1 year)
131.9%
Relative volume
0.34×

Market cap history

Month-end market cap since 2017, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.

PeriodMREOS&P 500DifferenceMREO per yearS&P 500 per year
1 month-9.4%-4.0%−5.4 pts
3 months-10.8%-5.0%−5.8 pts
Year to date-34.1%+8.2%−42.4 pts
1 year-84.5%+11.2%−95.7 pts
3 years-86.8%+68.5%−155.3 pts-49.1%+19.0%
5 years-86.6%+67.3%−153.9 pts-33.1%+10.8%
10 years+2645.0%+291.6%+2353.4 pts+39.3%+14.6%

Ten years at a glance

Fiscal years 2016 to 2025 and trailing twelve months, USD

Revenue

–

Operating income

-$30.40M

Net income

-$26.94M

EPS, diluted

-$0.04

Free cash flow

-$22.09M
Reported periodTrailing twelve months

Press releases

Releases Mereo BioPharma filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Mereo BioPharma

Pharmaceutical Preparations

Mereo BioPharma Group plc is a biopharmaceutical company that develops therapeutics for rare diseases. The organization acquires drug candidates with prior development history from larger pharmaceutical corporations to advance clinical programs. Its principal late-stage clinical assets include setrusumab, a monoclonal antibody under evaluation for osteogenesis imperfecta, and alvelestat, an oral neutrophil elastase inhibitor designed for alpha-1 antitrypsin deficiency-associated lung disease. It also maintains vantictumab for autosomal dominant osteopetrosis Type 2. The company focuses on clinical-stage segments, serving patient populations with specialized medical conditions and collaborating with commercial biopharmaceutical partners.

Company profile, executives and history

Mereo BioPharma stock: common questions

What is Mereo BioPharma's stock price?

MREO closed at $0.27 on Nov 17, 2026, down 10.00% on the day. Over the past 52 weeks it traded between $0.20 and $2.37.

What is Mereo BioPharma's market cap?

Mereo BioPharma was worth $43.84M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.

What is MREO's P/E ratio?

Mereo BioPharma lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.04), so it has no meaningful P/E ratio.

How much revenue does Mereo BioPharma make?

Mereo BioPharma reported revenue of $500.00K for fiscal 2025.

Does Mereo BioPharma pay a dividend?

No. Mereo BioPharma has not paid a cash dividend over the last twelve months.

When does Mereo BioPharma report earnings next?

Mereo BioPharma is expected to report Q4 FY2026 results on Mar 18, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.

How has MREO stock performed over the past year?

Including dividends, MREO returned -84.5% over the past year, against +11.2% for the S&P 500.

Who are Mereo BioPharma's competitors?

Companies most similar to Mereo BioPharma by business, industry and size include RLYB, SLN, XTLB, SCNX, SPRB.

See a number that looks wrong?